JPMorgan Chase & Co. Issues Pessimistic Forecast for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its price objective trimmed by JPMorgan Chase & Co. from $310.00 to $300.00 in a research report report published on Tuesday morning. The firm currently has an overweight rating on the conglomerate’s stock.

Other equities analysts have also recently issued reports about the company. Guggenheim started coverage on Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price objective for the company. UBS Group cut their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Royal Bank of Canada cut their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Finally, Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research report on Thursday, October 31st. Six equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $278.00.

Danaher Price Performance

Shares of NYSE DHR opened at $223.16 on Tuesday. The firm has a market capitalization of $161.19 billion, a P/E ratio of 42.59, a P/E/G ratio of 4.43 and a beta of 0.83. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The stock’s 50-day simple moving average is $235.89 and its two-hundred day simple moving average is $253.45. Danaher has a twelve month low of $221.34 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same period in the previous year, the company posted $2.09 earnings per share. As a group, equities analysts anticipate that Danaher will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is presently 20.61%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in DHR. Coronation Fund Managers Ltd. lifted its stake in shares of Danaher by 29.9% in the 2nd quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock valued at $1,596,000 after purchasing an additional 1,470 shares during the period. Ascent Group LLC lifted its stake in shares of Danaher by 30.2% in the 2nd quarter. Ascent Group LLC now owns 2,205 shares of the conglomerate’s stock valued at $551,000 after purchasing an additional 512 shares during the period. Quarry LP raised its stake in Danaher by 250.6% during the second quarter. Quarry LP now owns 298 shares of the conglomerate’s stock valued at $74,000 after buying an additional 213 shares during the last quarter. Regal Investment Advisors LLC raised its stake in Danaher by 1.9% during the second quarter. Regal Investment Advisors LLC now owns 8,581 shares of the conglomerate’s stock valued at $2,144,000 after buying an additional 157 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. raised its stake in Danaher by 5.0% during the second quarter. B. Riley Wealth Advisors Inc. now owns 11,035 shares of the conglomerate’s stock valued at $2,760,000 after buying an additional 527 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.